TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01733901

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSD
Description: Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
Study: NCT05529290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol + Thiocolchicoside
Description: Dexketoprofen Trometamol + Thiocolchicoside (25mg + 4mg) is a NSAID. It was given to the patients twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol + Paracetamol
Description: Dexketoprofen Trometamol + Paracetamol (25mg + 300mg) is a NSAID. It was given to the patients twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol (25mg)
Description: Dexketoprofen Trometamol (25mg) is a NSAID. It was given to the patients twice a day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol (500 mg) is a mild analgesic and antipyretic. It was given to the patients to take only if needed as max. dose 2000mg.
Study: NCT01252342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
Study: NCT02321618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BP measurement & pharmacy
Description: Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: BP educational materials
Description: Exposure to hypertension educational materials
Study: NCT03011580

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fultium-D3
Description: Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
Study: NCT00966303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation with diaphragmatic muscle training
Description: Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
Study: NCT01991938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-5584
Study: NCT05164679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multimodal training (MMT)
Description: Supervised multimodal exercise training (MMT) performed 1-2 hours weekly for 19 weeks
Study: NCT04613102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVCN583601 (3% Cannabidiol cream)
Description: Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVCN583601 (3% Cannabidiol cream)
Description: Topical application twice daily for 4 weeks (phase 2) and for 8 weeks (phase 3).
Study: NCT01551953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: 12 week tai chi class
Study: NCT03018912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep VS
Description: During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.~The subjective Sleep VS is composed of the following 2 questions:~1. How many days a week are you satisfied with your sleep?~2. How many days a week is sleepiness a problem?
Study: NCT05962918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perinal massage
Description: Perineal massage was administered to all pregnant women in the experimental group during both the labor and resting phases between contractions. The participants received an average of 5-10 minutes of perineal massage two, four and four to six times at the latent (0-3-cm cervical dilation), active (4-7-cm cervical dilation) and transition (8-10-cm cervical dilation) phases of labor, respectively. These women continued to receive perineal massage at every push throughout the second stage of labor. The researcher midwife gently widened the perineal muscles by making stretching movements with her fingers. Perineal massage was applied using all three of the from one edge to the other, U shape and pressure massage techniques. The researcher gently applied a rhythmic U pressure with both fingers, moving them on the vagina downwards about 3 to 9 o'clock. Each pressure movement was maintained laterally for 1-2 minutes towards the rectum.
Study: NCT00607568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine
Description: atomoxetine 40mg per day or placebo~For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II.
Study: NCT01551953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body breathing
Description: 12 week breathing class

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: 12 week education class
Study: NCT04009213

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiquiBand FIX8®
Description: An n-butyl-2-cyanoacrylate adhesive monomer and D\&C Violet #2 dye

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AbsorbaTack™
Description: An absorbable synthetic polyester copolymer derived from lactic and glycolic acid and is dyed with D\&C Violet No. 2.
Study: NCT04284943

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long limb Roux-en-Y reconstruction after subtotal gastrectomy
Description: The jejunum will be divided approximately 150 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 50 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Roux-en-Y reconstruction after subtotal gastrectomy
Description: The jejunum will be divided approximately 20 cm distal to the ligament of Treitz (Length of biliopancreatic limb). The gastrojejunostomy will be performed by end-to-end anastomosis and an anastomosis of the proximal end of the jejunum to the distal jejunum will be created approximately 30-45 cm distal from the gastrojejunal anastomosis (Length of Roux-en-Y limb).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Billroth II reconstruction after subtotal gastrectomy
Description: The duodenum will be transected approximately 2 cm distal to the pylorus and anastomosis will be performed between the gastric remnant and a loop of jejunum chosen approximately 20 cm distal to the ligament of Treitz (Length of afferent loop)
Study: NCT02591004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magesium sulphate
Description: \*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins \& 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: \*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Doppler on fetal middle cerebral artery
Description: both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Doppler on fetal middle cerebral artery
Description: both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
Study: NCT03489993

Intervention type: DIAGNOSTIC_TEST
Intervention: Ang II and Ang-(1-7)
Description: Measured in plasma and urine using radioimmunoassays.

Intervention type: DIAGNOSTIC_TEST
Intervention: FGF23 and klotho
Description: Measured using ELISA's.
Study: NCT03264794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial
Description: Gefitinib Tab （CTTQ），First medication,250mg；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib tablets (Yi Ruisha），First medication
Description: Gefitinib tablets (Yi Ruisha），First medication,250mg；

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
Description: From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.
Description: From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
Study: NCT03179579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC with neoadjuvant chemotherapy
Description: HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Systemic chemotherapy
Description: NACT 3 cycles +CRS +ACT 4-6 cycles
Study: NCT04320979

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: no internal mammary nodal irradiation
Description: chest wall and supraclavicular+-axillary nodal irradiation (50 Gy in 25 fractions or 43.5Gy in 15 fractions).
Study: NCT01474902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
Study: NCT04902534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naoqingzhiming Tablets (contains echinacoside 180mg)
Description: Single dose escalation and multiple dose escalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of Naoqingzhiming Tablets (without echinacoside)
Description: Single dose escalation and multiple dose escalation
Study: NCT02581358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scolioscan (Ultrasound imaging system)
Description: To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
Study: NCT03411850

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Orencia
Description: FDA approved biologic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04080869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retinyl palmitate
Description: topical retinyl palmitate loaded ethosomes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tretinoin
Description: topical tretinoin
Study: NCT04465123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone or hydrochlorothiazide
Description: Patients will be received spironolactone or hydrochlorothiazide in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone 100 mg every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide 50 mg every 12 hour for 72 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will be received spironolactone placebo or hydrochlorothiazide placebo in combination with intravenous furosemide according to patients' serum potassium levels.~If serum potassium levels ≤4 mEq/L, patients will be received spironolactone placebo every 12 hour for 72 hours.~If serum potassium levels \>4 mEq/L, patients will be received hydrochlorothiazide placebo every 12 hour for 72 hours.
Study: NCT01071096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.~At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm.
Study: NCT04520828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural repositioning
Description: The 10-min transdisciplinary intervention aimed (1) to facilitate and activate axial extension during standing and then during sitting; (2) to actively mobilize the trunk, cervical spine, and pelvic and shoulder girdles during standing and then during sitting; and (3) to adjust the seated position, as needed, with supports to ensure its maintenance throughout the experiment. Cushion, balls, boxes, or rolls were used to stabilize the final seated position.
Study: NCT05265143

Intervention type: OTHER
Group type: OTHER
Intervention: bolus/intermittant feeding
Description: sequential randomization

Intervention type: OTHER
Group type: OTHER
Intervention: bolus/intermittant feeding
Description: sequential randomization
Study: NCT03317574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botulinum toxin type A
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
Study: NCT02640066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Study: NCT00511953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin Extended Release tablets
Description: 1800mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin Extended Release tablets
Description: 1800mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 1800mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: 1800mg
Study: NCT03427541

Intervention type: PROCEDURE
Intervention: Surgeries
Description: Surgeries
Study: NCT01978158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: LPS is used to elicit an inflammatory response in all subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide
Description: LPS is used to elicit an inflammatory response in all subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide
Description: LPS is used to elicit an inflammatory response in all subjects
Study: NCT01922778

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D\&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.~For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter.
Study: NCT01372371

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin and Gentamycin
Description: 1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: 1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
Study: NCT01788982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Nintedanib should be administered orally at a dose of 200 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nintedanib
Description: Nintedanib should be administered orally at a dose of 200 mg twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00131677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disoproxil fumarate
Description: study product taken daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tenofovir disoproxil fumarate
Description: study product taken daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: study product taken daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: study product taken daily
Study: NCT05436886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurogabin (Gabapentin) 400 mg capsule
Description: All the subjects will receive a single dose of one capsule of either the Test Drug (Neurogabin 400 mg capsule) or Reference Drug (Parketin 400 mg capsule) in one period. if they receive Test in one period, they will alternatively receive Reference drug in the second period.
Study: NCT03009994

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair of uterine incision

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Repair of uterine incision

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exteriorization of the uterus

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non exteriorization of the uterus
Study: NCT02945098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Kinesio Taping
Description: Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
Study: NCT00779636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine
Description: Desloratadine 10 mg daily x 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo daily x 28 days
Study: NCT00313443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat tissue needle aspiration
Description: Small fat tissue sampling performed by needle aspiration.
Study: NCT01231802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eniluracil
Description: Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17